The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Publications
Osborn MJ, Panda S, Reineke TM, Tolar J, Nyström A. 2025. Progress in skin gene therapy: From the inside and out. Mol Ther. Mar 12:S1525-0016(25)00191-1. doi: 10.1016/j.ymthe.2025.03.017.
Röttele F, Zollner A, Mogler C, Yuksel M, Arikan C, Karl V, Aberle JH, Aberle SW, Kogler H, Vécsei A, Vodopiutz J, Salié H, Gräser A, Krimmel L, Martin P, Lurz E, Maier FI, Woelfle L, Nobre S, Goncalves I, Kern L, Schwemmle M, Boettler T, Hofmann M, Hasselblatt P, Thimme R, Tilg H, Müller T, Vogel GF, Bengsch B. 2025. Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19. Gut. Apr 5:gutjnl-2024-333880. doi: 10.1136/gutjnl-2024-333880.
Schlösser RM, Krumbach F, Corrales E, Andrieux G, Preisinger C, Liss F, Golzmann A, Boerries M, Becker K, Knüchel R, Garczyk S, Lüscher B. 2025. Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells. Mol Oncol. Apr 1. doi: 10.1002/1878-0261.70019.
Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. 2025. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000.
Fernandez-Orth J, Koyunlar C, Weiss JM, Gioacchino E, de Looper HWJ, Andrieux G, Ter Borg M, Zink J, Gonzalez Menendez I, Hoogenboezem R, Yigit BI, Gussinklo K, Mulet-Lazaro R, Wantzen C, Pfeiffer S, Molnar C, Bindels E, Bohler S, Sanders MA, Quintanilla-Martinez L, Wlodarski MW, Boerries M, Touw IP, Niemeyer C, Erlacher M, de Pater E. 2025. Hematological phenotypes in GATA2 deficiency syndrome arise from aging maladaptation to proliferation and somatic events. Blood Adv. 2025 Mar 26:bloodadvances.2024015106. doi: 10.1182/bloodadvances.2024015106.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency,
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
